Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Simcere Pharmaceutical Group (STU:S2P) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Simcere Pharmaceutical Group's Enterprise Value for the quarter that ended in Dec. 2025 was €3,033 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Simcere Pharmaceutical Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €239 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simcere Pharmaceutical Group EV-to-EBIT Related Terms
Simcere Pharmaceutical Group EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simcere Pharmaceutical Group EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Simcere Pharmaceutical Group's EV-to-EBIT falls into.
Simcere Pharmaceutical Group's current Enterprise Value is €3,022 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Simcere Pharmaceutical Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €239 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simcere Pharmaceutical Group (STU:S2P) has a EV-to-EBIT of 12.63 as of Aug. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Simcere Pharmaceutical Group and its competitors. This is 28% below median its historical median of 17.57. Over the past decade, Simcere Pharmaceutical Group's EV-to-EBIT has ranged from 9.38 to 37.41. According to the industry distribution chart, Simcere Pharmaceutical Group ranks #359 out of 690 companies in the Drug Manufacturers industry, placing it in the top 52%.
Is Simcere Pharmaceutical Group's EV-to-EBIT too high?
Simcere Pharmaceutical Group's current EV-to-EBIT of 12.63 is 28% below median its 10-year median of 17.57. Over the past 10 years, this metric has ranged from a low of 9.38 to a high of 37.41. The Drug Manufacturers industry median EV-to-EBIT is 15.12. Simcere Pharmaceutical Group's value of 12.63 is 16.4% below this industry median. Based on the distribution chart, Simcere Pharmaceutical Group ranks #359 out of 690 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Simcere Pharmaceutical Group has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Simcere Pharmaceutical Group's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Simcere Pharmaceutical Group ranks #359 out of 690 companies for EV-to-EBIT. This places Simcere Pharmaceutical Group in the lower half of its industry. The industry median EV-to-EBIT is 15.12. Simcere Pharmaceutical Group's value of 12.63 is 16.4% below this benchmark. Historically, Simcere Pharmaceutical Group's own EV-to-EBIT has ranged from 9.38 to 37.41 over the past decade. While the company's 10-year median is 17.57 vs. the industry median of 15.12, Simcere Pharmaceutical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.12, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Simcere Pharmaceutical Group's current EV-to-EBIT of 12.63 is 16.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Simcere Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simcere Pharmaceutical Group's current EV-to-EBIT is 12.63, which is 28% below median its own 10-year median of 17.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simcere Pharmaceutical Group stock overvalued right now?
Simcere Pharmaceutical Group (STU:S2P) has a current EV-to-EBIT of 12.63. The stock's GF Value™ is €1.16, compared to a current price of €1.26 — trading 8.6% above its estimated fair value. The current EV-to-EBIT is 12.63, which is 28% below median its 10-year median of 17.57 and 16.4% below the Drug Manufacturers industry median of 15.12. Simcere Pharmaceutical Group's overall GF Score™ is 94/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Simcere Pharmaceutical Group (STU:S2P), the current EV-to-EBIT is 12.63 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simcere Pharmaceutical Group (STU:S2P) Overvalued in 2026?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued.
The current stock price of €1.26 is trading 8.6% above its estimated GF Value™ of €1.16.
Key valuation signals for STU:S2P:
EV-to-EBIT: 12.63 (28% below median its 10-year median of 17.57)
GF Value™: €1.16 vs. price of €1.26 (8.6% above fair value)
Industry Position: 16.4% below the Drug Manufacturers median (#359 of 690)
No single metric tells the full story. See the STU:S2P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
94GF Score
Get the complete analysis for STU:S2P
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:S2P has been successfully added to your 
